BIOMARKER:

LDH-H

Entrez ID:

Related biomarkers:

‹

›

LDH-H LDH-H	Melanoma Melanoma	LDH-H LDH-H	Melanoma Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials	PD-L1 inhibitor Sensitive: B - Late Trials
LDH-H LDH-H	Melanoma Melanoma	LDH-H LDH-H	Melanoma Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials
LDH-H LDH-H	Gastric Cancer Gastric Cancer	LDH-H LDH-H	Gastric Cancer Gastric Cancer	ramucirumab Resistant: C3 – Early Trials	ramucirumab Resistant: C3 – Early Trials
LDH-H LDH-H	Melanoma Melanoma	LDH-H LDH-H	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	LDH-H LDH-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
LDH-H LDH-H	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	LDH-H LDH-H	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials	trastuzumab Resistant: C3 – Early Trials
LDH-H LDH-H	Melanoma Melanoma	LDH-H LDH-H	Melanoma Melanoma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
LDH-H LDH-H	Melanoma Melanoma	LDH-H LDH-H	Melanoma Melanoma	rivoceranib + camrelizumab Resistant: C3 – Early Trials	rivoceranib + camrelizumab Resistant: C3 – Early Trials